Cell Source, Inc.

Symbol: CLCS

PNK

0.0002

USD

Market price today

  • -0.0054

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 0.01M

    MRK Cap

  • 0.00%

    DIV Yield

Cell Source, Inc. (CLCS) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-22.58%

Return on Equity

0.39%

Return on Capital Employed

0.27%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Itamar Shimrat
Full-time employees:1
City:New York
Address:57 West 57th Street
IPO:2014-05-01
CIK:0001569340

Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.

Return on Investments

The company's asset efficiency, represented by a robust -22.583% return, is a testament to Cell Source, Inc.'s adeptness in optimizing resource deployment. Cell Source, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.388%. Furthermore, the proficiency of Cell Source, Inc. in capital utilization is underscored by a remarkable 0.274% return on capital employed.

Liquidity Ratios

Analyzing CLCS liquidity ratios reveals its financial health of the firm. The current ratio of 1.53% gauges short-term asset coverage for liabilities. The quick ratio (0.02%) assesses immediate liquidity, while the cash ratio (0.02%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio1.53%
Quick Ratio0.02%
Cash Ratio0.02%

Profitability Ratios

The effective tax rate stands at -7.72%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 127.78%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate-7.72%
Net Income per EBT100.00%
EBT per EBIT127.78%

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.06, and free cash flow per share, -0.06, depict cash generation on a per-share basis.

cards.indicatorcards.value
Operating Cash Flow per Share-0.06
Free Cash Flow per Share-0.06
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-0.25
Short Term Coverage Ratio-0.25

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 3814.72%, highlights its total liabilities relative to assets. With a debt-equity ratio of -0.59, we discern the balance between debt and equity financing. An interest coverage of -3.48 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio3814.72%
Debt Equity Ratio-0.59
Total Debt to Capitalization-144.51%
Interest Coverage-3.48
Cash Flow to Debt Ratio-0.25
Company Equity Multiplier-0.02

Per Share Data

Net income per share, -0.15, reflects the portion of profit attributed to each share. The book value per share, -0.36, represents the net asset value distributed per share, while the tangible book value per share, -0.36, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-0.15
Book Value Per Share-0.36
Tangible Book Value Per Share-0.36
Shareholders Equity Per Share-0.36
Interest Debt Per Share0.26

Growth Ratios

EBIT growth, -3.90%, and operating income growth, -3.90%, offer insights into operational profitability progression. The net income growth, 24.37%, showcases bottom-line expansion, and the EPS growth, 28.57%, measures the growth in earnings per share.

cards.indicatorcards.value
EBIT Growth-3.90%
Operating Income Growth-3.90%
Net Income Growth24.37%
EPS Growth28.57%
EPS Diluted Growth28.57%
Weighted Average Shares Growth5.19%
Weighted Average Shares Diluted Growth5.19%
Operating Cash Flow Growth7.10%
Free Cash Flow Growth7.10%
5-Year Operating CF Growth per Share-5.44%
3-Year Operating CF Growth per Share1.35%
5-Year Net Income Growth per Share-28.85%
3-Year Net Income Growth per Share12.15%
5-Year Shareholders Equity Growth per Share-113.07%
3-Year Shareholders Equity Growth per Share-78.93%
5-Year Dividend per Share Growth per Share-100.00%
3-Year Dividend per Share Growth per Share-100.00%
Asset Growth30.62%
Book Value per Share Growth-22.23%
Debt Growth22.18%
R&D Expense Growth50.84%
SGA Expenses Growth-19.15%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 37,292,285.65, captures the company's total value, considering both debt and equity. Income quality, 0.61, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value37,292,285.65
Income Quality0.61
Graham Number1.10
Return on Tangible Assets-1260.90%
Graham Net Net-0.37
Working Capital-12,633,895
Tangible Asset Value-12,633,895
Net Current Asset Value-12,633,895
Invested Capital-1
Average Payables451,683
ROIC-16953053.14%
ROE0.41%

Valuation Ratios

Ratios like price to free cash flows, -0.01, and price to operating cash flows, -0.01, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Cash Flow Ratio-0.01
Enterprise Value Multiple2.15
Price to Operating Cash Flow Ratio-0.01
Price to Free Cash Flows Ratio-0.01
Price to Tangible Book Ratio-2.34
Enterprise Value Over EBITDA-8.93
EV to Operating Cash Flow-11.88
Earnings Yield-17.45%
Free Cash Flow Yield-10.60%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Cell Source, Inc. (CLCS) on the PNK in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.005 in 2024.

What is the ticker symbol of Cell Source, Inc. stock?

The ticker symbol of Cell Source, Inc. stock is CLCS.

What is company IPO date?

IPO date of Cell Source, Inc. is 2014-05-01.

What is company current share price?

Current share price is 0.000 USD.

What is stock market cap today?

The market cap of stock today is 7709.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 1.